Fig. 2: Relative effect of prevention therapies in individuals at risk for T1D.

Forest plot showing hazard ratio with 95% confidence intervals for primary prevention studies in genetically at-risk individuals and secondary prevention studies in individuals with elevated islet autoantibody titers. Primary prevention studies are divided by outcome—either time to islet autoantibody positivity or time to diabetes. All secondary prevention studies used time to diabetes as a primary outcome. DPT-1 Diabetes Prevention Trial Type 1 ; GAD glutamic acid decarboxylase.